Charles River Laboratories International (CRL) has seen several developments recently, eliciting mixed reactions in the market. Some of these events include the slashing of the company's price target to $210.00 by Bank of America. Barclays PLC and TD Private Client Wealth LLC also lowered their holdings in CRL. Despite that, the National Bank of Canada FI, Neo Ivy Capital Management, Janus Henderson Group PLC, and iA Global Asset Management, among others, have boosted their stake in the firm. CRL announced its
Third-Quarter 2024 results and presented strategic insights at multiple investor conferences which included Evercore ISI, UBS, Jefferies, and Baird. In a significant step, CRL rolled out a
Global Biotech Incubator Program targeted at aiding early-stage companies. Strategic alliances were forged with NJ Bio, Autobahn Labs, and CEBINA to expedite various biotech developments, including ADC manufacturing and neuroscience research. Following the quarterly earnings report that was met with conjecture on the street, CRL expected a reduction in sales while launching the new Retrogenix® Non-Human Protein Library. Meanwhile, market forecasts pertaining to the firm ranged from warnings of a 'strained balance sheet' to recommendations for keeping an eye on CRL as a potential watchlist candidate.
Charles River Laboratories International CRL News Analytics from Wed, 27 Mar 2024 07:00:00 GMT to Sat, 14 Dec 2024 16:44:46 GMT -
Rating -5
- Innovation 2
- Information 6
- Rumor -2
